Licensing agreements are an important source of funding and revenue for many biotech companies, particularly those without an approved product generating commercial sales. A single deal can include an upfront payment, a series of development and regulatory milestones, sales-based milestones, and ongoing royalties, and getting each one right under ASC 606 comes down to a handful of judgment calls:
For companies preparing for a raise, a strategic partnership, or an eventual acquisition, these calls often become a focal point of the life sciences due diligence process. Buyers and investors want to understand whether reported revenue reflects real economic progress or simply the timing of cash receipts, and inconsistent answers to these questions are usually where their questions start.
A typical biotech out-licensing arrangement can bundle several promises into one contract: a license to intellectual property, participation in a joint steering committee, manufacturing support, and sometimes co-development responsibilities. Not every one of those promises counts as something the company needs to account for separately. A steering committee, for instance, is often administrative rather than a service the licensor is actually delivering, in which case it doesn't get its own slice of the payment.
Once the promises in a deal are identified, the next question is whether they stand on their own or are bundled together as one overall commitment. A license paired with manufacturing know-how transfer or ongoing research support might be distinct from those services, or it might not be, depending on how much the licensee's ability to use the license actually depends on the rest of the deal. Getting this call wrong is what most often turns a license that should be straightforward into a multi-year recognition pattern nobody planned for.
Separately from the distinctness question, the license itself gets classified as functional or symbolic IP, and that classification decides whether it's recognized all at once or spread out over time. Most biotech intellectual property, including clinical-stage compounds and proprietary technology, is functional, even years before regulatory approval. Bundling a license with committee work or technology transfer doesn't turn functional IP into symbolic IP on its own, and treating it that way is a common misstep.
What can change the timing is whether the licensor is still expected to meaningfully develop the underlying IP after the deal closes. When that's the case, the license behaves less like a completed handoff and more like an ongoing right to whatever the licensor keeps building, which pushes recognition out over time instead of all at once at signing.
Once the distinct pieces of a deal are identified, the upfront payment gets split across them, and not on a simple pro-rata basis.
Consider a hypothetical $40 million upfront payment for a license to a Phase 2 oncology asset, where the licensor also commits to leading a joint development committee and transferring manufacturing know-how over 18 months.
If the license is distinct from those services, a company might allocate $30 million to the license and $10 million to the services, with the service portion recognized as that work happens. If the committee and know-how obligations turn out not to be distinct from the license, the whole $40 million gets recognized together instead, on whatever pattern fits the overall promise, not simply spread evenly over 18 months.
Either way, the allocation needs real support behind it. Companies with well-organized R&D cost accounting practices often have much of the underlying data this analysis requires already on hand. Companies that treat the allocation as a rough estimate rather than a documented, defensible split create inconsistency from deal to deal, and that inconsistency is exactly what diligence teams and auditors probe first.
Milestone payments break down into a few distinct types, and each one clears a different bar before it can be recognized.
Milestone payments tied to clinical or regulatory events, like dosing a first patient or receiving FDA approval, sit close to the broader discipline of clinical trial accounting, and they don't get recognized just because they're contractually likely. They have to clear a recognition threshold first, and clinical development carries enough scientific and regulatory risk that most companies don't clear it until the event has actually happened or is essentially certain. Recognizing that revenue earlier, based on an optimistic read of the odds, is one of the more common ways licensing revenue gets overstated.
Clearing that threshold isn't the end of the analysis. The company still has to work out which part of the deal the milestone actually belongs to. If it relates to something already delivered, such as a license that has already been transferred, the payment is typically recognized right away. If it relates to something still being performed, it gets recognized over what's left of that work instead. The result can look a lot like the milestone accounting biotech companies used under the older revenue rules, even though the reasoning behind it now works differently.
Milestones triggered by hitting a sales threshold are generally treated like royalties, recognized only once the underlying sales actually happen rather than when the threshold becomes likely. That treatment isn't automatic for every contract, so it's worth confirming rather than assuming.
Companies running several licensing deals with staggered milestones benefit from tracking each one in a single place, including how it was classified and what triggers its recognition. Without that discipline, treatment tends to drift across deals signed in different years, which complicates both audit readiness and due diligence during a fundraise or acquisition.
Royalty revenue tied to a licensee's product sales follows its own rule: it can't be recognized before the underlying sales happen, regardless of how the rest of the license was treated. In practice, that usually means waiting on the licensee to report sales data, which often lags a full quarter behind the activity itself. Companies that can reasonably estimate sales before that report arrives may need to record an accrual and true it up later, rather than simply waiting on the licensee's timeline.
Strong biotech financial planning processes build that lag into the close, into forecasts, and into how numbers get communicated to investors, rather than treating royalty income as a predictable, evenly distributed stream.
|
Revenue Component |
Recognized When |
|
Distinct license to functional IP |
Generally all at once, when control of the license transfers |
|
Distinct license to symbolic IP |
Over time, as the licensor keeps performing |
|
Development and regulatory milestones |
Once the outcome is essentially certain or has occurred |
|
Sales-based milestones |
When the underlying sales occur |
|
Royalties |
When the underlying sales occur, or later if the related work is still being performed |
This is a starting reference, not a substitute for working through the judgment calls behind each row.
These judgment calls only hold up under scrutiny if they're documented at the point the deal is signed, not reconstructed later when an auditor or acquirer asks for support. That means reviewing each new licensing agreement's promises, distinctness conclusions, and allocation estimates before the deal closes, and keeping that analysis on file as a matter of policy rather than ad hoc judgment made deal by deal.
Diligence teams evaluating a biotech company ahead of a fundraise or acquisition tend to focus first on exactly this kind of documentation, since inconsistent treatment across licensing deals creates risk around reported revenue. Companies that maintain this discipline as part of a broader biotech accounting framework are far better positioned when those questions arrive.
Clean licensing revenue recognition comes from working through these judgment calls deliberately at signing, not from any single classification decision. What's promised, what's distinct, how the license is classified, how the payment is split, and when variable amounts are solid enough to recognize are separate questions that need to hold up individually and connect to one another. Getting that sequence right protects the integrity of reported revenue and gives investors, boards, and acquirers confidence in the numbers behind the science.
Our team at G-Squared Partners helps life sciences and biotech companies work through that sequence early, build revenue recognition policies that hold up under audit and diligence scrutiny, and translate complex licensing terms into financial reporting stakeholders can trust.
Our life sciences outsourced CFO services help growth-stage biotech companies apply ASC 606 correctly from deal signing through royalty reporting. Schedule a free consultation to learn how our professionals can help you strengthen revenue recognition practices before they come under scrutiny.